<PAGE>
FORM 8-K
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
January 6, 1997
ROBERTS PHARMACEUTICAL CORPORATION
- --------------------------------------------------------------------------------
(exact name of registrant as specified in its charter)
New Jersey 1-1-432 22-2429994
- ---------------- -------------- -----------------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Address of principal executive offices, including zip code)
Registrant's telephone number, including area code: 908-389-1182
Meridian Center II
4 Industrial Way West
Eatontown, New Jersey 07724
- --------------------------------------------------------------------------------
(Former name or former address, if changed from last report)
<PAGE>
-2-
Item 5. Other Events
------------
Roberts Pharmaceutical Corporation announced today an exclusive
license from Wyeth Laboratories, U.K., a subsidiary of American Home Products,
to market and distribute Lodine in the United Kingdom and the Republic of
Ireland. The agreement includes Lodine SR, a patent protected, once-a-day
formulation of this prescription analgesic.
Lodine is a nonsteroidal anti-inflammatory drug indicated for
acute and long-term use in osteoarthritis and rheumatoid arthritis. The product
line has an established base of revenues and profits in the U.K., but is not
currently marketed in the Republic of Ireland. The marketing of Lodine by
Roberts has already begun in the U.K. and plans are being put in place for the
future launch in the Republic of Ireland.
Lodine fits strategically into the product portfolio of Monmouth
Pharmaceuticals, Roberts wholly owned U.K. subsidiary. Lodine has great
marketing potential for Roberts' European operations as Monmouth has established
marketing momentum in the area of analgesics.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of
1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
ROBERTS PHARMACEUTICAL CORPORATION
----------------------------------
(Registrant)
Date: January 9, 1997 By: /s/ Anthony A. Rascio
-------------------------------
Anthony A. Rascio
Vice President
